Form 4: Soleno Therapeutics SVP Acquires Equity Grants

Soleno Therapeutics' SVP of Global Clinical Operations and Patient Advocacy, Kristen Yen, acquired 10,400 restricted stock units and 11,900 employee stock options.

Summary

• Kristen Yen, SVP Global Clinical Operations and Patient Advocacy at Soleno Therapeutics Inc. (SLNO), reported an acquisition of company securities.
• On January 21, 2026, Yen acquired 10,400 restricted stock units (RSUs) of Common Stock at a price of $0.
• These RSUs are scheduled to vest 100% on December 15, 2027, contingent on continued service as a Service Provider.
• Additionally, on January 21, 2026, Yen acquired 11,900 employee stock options with an exercise price of $43.65 and an expiration date of January 21, 2036.
• These options will vest at a rate of 1/48th on February 1, 2026, and each one-month anniversary thereafter, also subject to continued service.
• Following these transactions, Yen beneficially owns 37,639 shares of Common Stock (including RSUs) and 11,900 derivative securities (options).
• The transactions were made pursuant to a Rule 10b5-1(c) pre-planned contract for the purchase or sale of equity securities.

Sentiment

Score: 7

Explanation: The filing indicates an increase in insider ownership through equity grants, which is generally positive as it aligns executive interests with shareholder value. The transactions are part of a pre-planned compensation structure.

Positives

• Increased insider ownership through RSU and option grants aligns management interests with shareholder value.
• The grants incentivize long-term commitment and performance from a key executive, Kristen Yen.

Future Outlook

The vesting schedules for the RSUs and stock options extend into 2027 and 2036, respectively, indicating a long-term incentive structure for the reporting person, contingent on continued service to the company.

Industry Context

The granting of restricted stock units and stock options to senior executives is a common practice in the biotechnology and pharmaceutical industry to attract, retain, and motivate key talent, aligning their interests with the company's long-term success and shareholder value creation.

Comparison to Industry Standards

• The use of RSUs and stock options as executive compensation is standard practice across the biotech and pharmaceutical sectors, comparable to incentive structures at companies like Biogen, Gilead Sciences, or Amgen.
• Vesting schedules, such as the 100% vesting on a specific future date for RSUs and monthly vesting for options, are typical mechanisms designed to encourage long-term employee retention and performance.

Related Party Transactions

• The reported transactions involve the grant of equity compensation (restricted stock units and stock options) to Kristen Yen, an officer of Soleno Therapeutics Inc., which constitutes a related party dealing.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value due to equity ownership.
• Employees: Reflects standard executive compensation practices, potentially signaling stability in leadership.

Next Steps

• Continued service by Kristen Yen to meet vesting conditions for RSUs and stock options.
• Vesting of 1/48th of stock options monthly starting February 1, 2026.
• Full vesting of RSUs on December 15, 2027.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation in the form of RSU and stock option grants. While these grants align management interests with shareholders, they do not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. It's a standard compensation event, suggesting a 'hold' position unless other fundamental factors change.

Keywords

Soleno Therapeutics, SLNO, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Executive Compensation, Kristen Yen, Equity Incentive Plan, Rule 10b5-1